Skip Navigation

Home > EMCDDA initial report on the new psychoactive substance N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1-ethanamine (isotonitazene), Initial reports.

European Monitoring Centre for Drugs and Drug Addiction. (2020) EMCDDA initial report on the new psychoactive substance N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1-ethanamine (isotonitazene), Initial reports. Luxembourg: Publications Office of the European Union. 22 p.

[img]
Preview
PDF (Isotonitazene initial report) - Published Version
409kB

Isotonitazene is a synthetic opioid analgesic monitored by the EMCDDA as a new psychoactive substance through the European Union Early Warning System since 2019. Based on potential public health risks, an initial report has been prepared and submitted to the Commission and the Member States, in accordance with Article 5b of Regulation (EC) No 1920/2006 (as amended). Its purpose is to provide scientific evidence to the Commission to allow it to make an informed decision regarding whether or not there is a need to request a risk assessment on a new psychoactive substance.

Item Type
Evidence resource
Publication Type
Report
Drug Type
New psychoactive substance
Date
April 2020
Pages
22 p.
Publisher
Publications Office of the European Union
Corporate Creators
European Monitoring Centre for Drugs and Drug Addiction
Place of Publication
Luxembourg
EndNote
Accession Number
HRB (Electronic Only)
Related URLs

Repository Staff Only: item control page